Compare Invesco DB Commodity Index Tracking Fund (DBC) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Commodity Index Tracking Fund vs Sanofi SA — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $28.77, while Sanofi SA trades at $43.67 (market cap $102.91B). The key difference: Sanofi SA pays a 5.6% dividend while Invesco DB Commodity Index Tracking Fund pays none, and Invesco DB Commodity Index Tracking Fund is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| DBC | SNY | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $31.69 | $52.34 |
52-Week Low | $21.62 | $41.33 |
Market Cap | — | $102.91B |
Enterprise Value | — | $119.39B |
Dividend Yield | — | 5.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBC, the Invesco DB Commodity Index Tracking ETF, trades at $28.33, up 2.94% today, with a bullish technical signal from moving averages and oscillators. Recent news highlights its role as an inflation hedge, with a 52-week high noted in April 2026. The ETF provides diversified commodity exposure, benefiting from oil supply shocks and safe-haven demand, though key financial ratios like P/E and P/S are not applicable for this fund structure.
Outlook remains positive due to strong momentum and inflation hedging appeal, but risks include commodity price volatility and geopolitical factors. Analyst sentiment is supportive, with the ETF favored in balanced portfolios for moderate-risk investors seeking commodity diversification amid market uncertainty.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco DB Commodity Index Tracking Fund
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
